MedPath

Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors

Not Applicable
Completed
Conditions
Metabolic Syndrome
Interventions
Other: Placebo (without any active ingredients)
Dietary Supplement: Natural supplement containing chlorogenic acid and luteolin
Registration Number
NCT03444558
Lead Sponsor
University of Palermo
Brief Summary

Clinical trial about beneficial effects of natural ingredient containing chlorogenic acid and luteolin on liver health and conditions related to liver (such as metabolic syndrome) for general body health.

Detailed Description

This is one randomized, double-blind, placebo-controlled study. The purpose of the present study is to evaluate and/or elucidate the role of the natural supplement, containing chlorogenic acid (10-12%) and luteinyl-7-glucoside (2-4%), on cardio-metabolic risk factors.

The research hypothesis is to evaluate whether natural supplement containing chlorogenic acid and luteolin (Puraltilix, BIONAP SRL, Catania, Italy) may improve several cardio-metabolic parameters in subjects with the metabolic syndrome.

All subjects will be evaluated at baseline and after 6 months of treatment (with natural supplement or placebo).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Men and women aged >18 years with the metabolic syndrome (as defined by the international criteria: Alberti KG, et al. Circulation. 2009; 120: 1640-5);
  • BMI> 25 kg/m^2;
  • Subjects able to swallow whole tablets;
  • Informed consent obtained prior to any study-related activities.
Exclusion Criteria
  • Pregnancy or willingness to become pregnant;
  • Severe liver dysfunction (ALT >2.5 times upper limit of normal);
  • Severe renal failure (eGFR<60 mL/min/1.73 m2 using the MDRD formula);
  • Severe infections at the discretion of the investigator (such as HIV, HBV and HCV);
  • History or presence of malignant neoplasms within the last 5 years.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo (without any active ingredients)50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
Dietary SupplementNatural supplement containing chlorogenic acid and luteolin50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
Primary Outcome Measures
NameTimeMethod
Effect of natural supplement on metabolic parameters including waist circumferenceChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including waist circumference (cm).

Effect of natural supplement on metabolic parameters including plasma lipidsChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol HDL-C) (mmol/l), while low-density lipoprotein cholesterol (LDL-C) will be calculated using the Friedewald formula.

Effect of natural supplement on metabolic parameters including body weight and Body Mass Index (BMI)Change from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including body weight (kg) and height (m) that will be combined to report BMI in kg/m\^2.

Effect of natural supplement on metabolic parameters including glucose metabolism parametersChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma glycemia (mmol/l).

Effect of natural supplement on metabolic parameters including plasma insulinemia and HOMA (homeostatic model assessment) indexChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma insulinemia (pmol/L) that with glycemia will be combined to report HOMA index.

Secondary Outcome Measures
NameTimeMethod
Effect of natural supplement on cardio-metabolic parameters including subclinical atherosclerosisChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including subclinical atherosclerosis assessed by carotid intima-media thickness (CIMT) (mm).

Effect of natural supplement on cardio-metabolic parameters including plasma cytokinesChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including plasma cytokines (inflammatory markers and adipokines) (pg/ml), that will be assessed using available enzyme-linked immunosorbent assay (ELISA) kits.

Effect of natural supplement on cardio-metabolic parameters including plasma lipoproteinsChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including atherogenic lipoproteins as well as the analysis of the full spectrum of lipoprotein subclasses by gel electrophoresis.

Effect of natural supplement on cardio-metabolic parameters including fatty liver indexChange from baseline to 6 months of the supplementation

Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including fatty liver index, a noninvasive method used for steatosis detection and quantification.

Trial Locations

Locations (1)

University Hospital of Palermo

🇮🇹

Palermo, Palrmo, Italy

© Copyright 2025. All Rights Reserved by MedPath